The trial doesn't answer the real question: is the new combination better than what we're already doing?
At the opening of ASCO 2026, oncologists gathered around two new treatment combinations for advanced lung cancer patients who lack targetable genetic mutations — the majority of those diagnosed. Both trials extended the time before disease progressed, and both left the field wrestling with a question as old as medicine itself: what does progress mean when the measuring stick may be imprecise? The answers matter enormously, because the patients waiting for them have few alternatives and little time.
- Two major trials at ASCO 2026 claimed advances in advanced non-small cell lung cancer, but each carried a methodological shadow that tempered the celebration.
- The OptiTROP-Lung05 trial showed a striking 70% response rate for sacituzumab tirumotecan plus pembrolizumab, yet compared the combination against immunotherapy alone — not the chemotherapy-immunotherapy standard most patients already receive.
- A Chinese phase III trial demonstrated that adding anlotinibe to benmelstobart and chemotherapy nearly doubled progression-free survival versus a regional standard, but the comparator drug is not used in Western oncology, limiting global applicability.
- Toxicity is a real cost: both combinations brought increased rates of anemia, immune-related side effects, and other adverse events that will require careful clinical management.
- Overall survival data remain immature across both studies, leaving the field without its most definitive measure — whether patients actually lived longer, not merely longer before their cancer grew again.
- The field is moving, but the destination is still contested: new options exist, efficacy gains are real, and the debate over which patients benefit most — and compared to what — is far from settled.
The first day of ASCO 2026 centered on a pressing clinical problem: how to treat the largest group of advanced lung cancer patients — those whose tumors carry no actionable genetic mutations. Two trials stepped forward with answers, and both sparked as much debate as optimism.
The OptiTROP-Lung05 trial tested sacituzumab tirumotecan, an antibody-drug conjugate targeting TROP2, alongside pembrolizumab in 413 PD-L1-positive patients without EGFR or ALK mutations. The combination dramatically outperformed pembrolizumab alone — a 70% response rate versus 42%, and a hazard ratio of 0.38 for progression-free survival. The benefit was especially pronounced in patients with intermediate PD-L1 expression, a group that typically receives chemoimmunotherapy as standard care. But that observation exposed the trial's central weakness: it never compared the new combination against that standard. The most relevant question — does this beat chemoimmunotherapy? — went unanswered. Toxicity also rose, with more anemia, neutropenia, and mucositis in the combination arm.
The second study, conducted entirely within China's health system, tested benmelstobart combined with chemotherapy and anlotinibe against tislelizumab plus chemotherapy in non-squamous lung cancer patients. The three-drug regimen extended median progression-free survival from 8.3 to 14.4 months, with benefits seen across PD-L1 subgroups. Safety was considered manageable. The limitation, however, was geographic and systemic: the comparator regimen is not standard outside China, making the results difficult to translate to North American or European practice.
What both trials share is a kind of productive incompleteness. They demonstrate real gains — longer disease control, higher response rates — while leaving the deeper question open: are these combinations genuinely superior to what patients already receive, or are they winning against a weaker opponent? Without mature overall survival data and without head-to-head comparisons against current global standards, the field has new tools but not yet the full map for using them wisely.
The first day of ASCO 2026 brought a cluster of new treatment combinations for advanced lung cancer patients without actionable genetic drivers—the largest population of newly diagnosed cases. Two studies dominated the conversation, each claiming progress, each raising questions about what progress actually means.
The OptiTROP-Lung05 trial, published simultaneously in The Lancet, tested sacituzumab tirumotecan, a new antibody-drug conjugate targeting TROP2, paired with pembrolizumab against pembrolizumab alone in 413 patients with advanced non-small-cell lung cancer that was PD-L1 positive but lacked EGFR or ALK mutations. The combination halted disease progression longer than the single drug: the median progression-free survival was not reached in the combination arm, compared to 5.6 months with pembrolizumab alone (hazard ratio 0.38). The response rate climbed to 70 percent with the combination versus 42 percent with pembrolizumab alone—a 28-point gap. In patients with the highest PD-L1 expression (≥50%), the benefit was more modest. But in those with intermediate PD-L1 levels (1–49%), the hazard ratio dropped to 0.28, suggesting the combination worked better in a population that normally receives chemotherapy plus immunotherapy as standard care. Global survival data remained immature, though early signals favored the combination.
The cost came in toxicity. Hematologic side effects—anemia, neutropenia—appeared more frequently in the combination arm, along with mouth sores and hair loss. Oncologists noted a fundamental problem: the trial compared the new combination against immunotherapy alone in a patient population where chemotherapy plus immunotherapy is already routine. The OptiTROP-Lung05 design left a gap in the evidence. To know whether sacituzumab tirumotecan plus pembrolizumab truly improves on current practice, you would need to compare it directly against chemotherapy plus pembrolizumab—a comparison the trial did not provide. The benefit in the intermediate PD-L1 group was striking, but it came from an exploratory subgroup analysis, not the primary design.
The second major study was exclusively Chinese: a phase III trial of benmelstobart, an anti-PD-L1 antibody, combined with chemotherapy and anlotinibe, a multi-targeted angiogenesis inhibitor, versus tislelizumab plus chemotherapy in patients with advanced non-squamous lung cancer without EGFR, ALK, or ROS1 mutations. The three-drug combination extended median progression-free survival to 14.4 months from 8.3 months with the standard approach—a hazard ratio of 0.67. The benefit held across most subgroups regardless of PD-L1 expression. Safety was manageable: anemia, low white blood cell counts, liver enzyme elevation, high blood pressure, and protein in the urine appeared most often.
Both trials offered something real—longer time before disease progressed, higher response rates—but both left clinicians weighing trade-offs. The OptiTROP-Lung05 study raised the question of whether a new drug combination truly beats the current standard or simply beats a weaker comparator. The benmelstobart trial, conducted in a single health system with its own approved drugs, offered no direct comparison to the immunotherapy regimens used in North America or Europe. Neither study provided mature overall survival data, the ultimate measure of whether patients lived longer, not just longer before their cancer grew again. What emerges is a field in motion—new options appearing, efficacy gains real but uneven, and the fundamental question of which patients benefit most still requiring clearer answers.
Notable Quotes
Chemotherapy plus immunotherapy is already routine for patients with intermediate PD-L1 expression, making the choice of comparator in OptiTROP-Lung05 a significant limitation.— Clinical commentary on trial design
The Hearth Conversation Another angle on the story
Why does it matter which drug you compare the new combination against?
Because if you only compare a new drug to a weak comparator, you can't tell if it's actually better than what doctors are already using. OptiTROP-Lung05 compared sacituzumab plus pembrolizumab against pembrolizumab alone, but chemotherapy plus pembrolizumab is already standard for many of these patients. So the trial doesn't answer the real question: is the new combination better than what we're already doing?
The response rate jumped from 42 to 70 percent. That sounds like a big difference.
It is. But response rate—tumors shrinking—doesn't always mean patients live longer. That's why oncologists wait for overall survival data. The OptiTROP-Lung05 team hasn't had enough time to see how many patients in each group actually died. The early signal looks good, but it's not the final word.
What about the benmelstobart study? It showed 14 months versus 8 months.
That's a real difference in progression-free survival. But again, it's a Chinese trial using drugs approved in China, compared against a Chinese standard. We don't know how it would perform against the immunotherapy regimens used in the United States or Europe. It's good data for Chinese patients, but it doesn't automatically translate elsewhere.
Both studies had more side effects in the treatment arms.
Yes. Sacituzumab brought hematologic toxicity—low blood counts, mouth sores. Benmelstobart brought anemia, liver problems, high blood pressure. These are manageable, but they're real burdens. You're asking patients to tolerate more toxicity in exchange for a longer window before their cancer progresses. That's a conversation each patient has to have with their doctor.
So neither study is definitive?
Not quite. OptiTROP-Lung05 is definitive about one thing: the combination works better than pembrolizumab alone. But whether it works better than chemotherapy plus pembrolizumab—the actual clinical question—remains open. Benmelstobart is definitive for its population in China, but its relevance elsewhere depends on how similar those patients are to others and whether the drugs are even available.